Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SKion GmbH
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.
Pfizer will develop the novel antifungal fosmanogepix. The big pharma has made several other recent anti-infective deals, including when it expanded its BioNTech vaccine alliance to include COVID-19.
In an interview, CEO Rob Armstrong said the company has created “a lot optionality” for how it can develop the programs it takes on from the big pharma’s portfolio management.
Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe.
- Other Names / Subsidiaries
- Altana AG